ArticleESMO open2025

Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis.

G Trovato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.